This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BDSI BioDelivery Sciences International (BDSI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About BioDelivery Sciences International Stock (NASDAQ:BDSI) Get BDSI alerts:Sign Up Key Stats Today's Range$5.59▼$5.6050-Day Range$5.54▼$5.6052-Week Range$2.50▼$5.62Volume2.09 million shsAverage Volume3.34 million shsMarket Capitalization$577.05 millionP/E Ratio6.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc. Read More BioDelivery Sciences International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreBDSI MarketRank™: BioDelivery Sciences International scored higher than 37% of companies evaluated by MarketBeat, and ranked 733rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for BioDelivery Sciences International. Earnings and Valuation3.1 / 5Proj. Earnings Growth73.68% Earnings GrowthEarnings for BioDelivery Sciences International are expected to grow by 73.68% in the coming year, from $0.38 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioDelivery Sciences International is 6.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 278.84.Price to Earnings Ratio vs. SectorThe P/E ratio of BioDelivery Sciences International is 6.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 80.30.Price to Book Value per Share RatioBioDelivery Sciences International has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BDSI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioDelivery Sciences International does not currently pay a dividend.Dividend GrowthBioDelivery Sciences International does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-2.18 Short InterestThere is no current short interest data available for BDSI. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for BioDelivery Sciences International this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioDelivery Sciences International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.98% of the stock of BioDelivery Sciences International is held by insiders.Percentage Held by Institutions64.40% of the stock of BioDelivery Sciences International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioDelivery Sciences International's insider trading history. Receive BDSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BDSI Stock News HeadlinesVaxart Appoints W. Mark Watson as Lead Independent Director and Encourages Stockholder Participation in Upcoming Vote on Reverse Stock SplitSeptember 17, 2025 | quiverquant.comQFlorida International UniversitySeptember 14, 2023 | usnews.comThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction. | Brownstone Research (Ad)International High School for Health SciencesMay 6, 2023 | usnews.comInternational climate change bodies win humanity awardOctober 15, 2022 | omaha.comOPerilous Reversal Watch: BioDelivery Sciences International (BDSI)September 16, 2022 | thestreet.comScienceSeptember 13, 2022 | npr.orgNCollegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | seekingalpha.comSee More Headlines BDSI Stock Analysis - Frequently Asked Questions How were BioDelivery Sciences International's earnings last quarter? BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to analysts' expectations of $42.05 million. BioDelivery Sciences International had a net margin of 50.90% and a trailing twelve-month return on equity of 21.25%. What other stocks do shareholders of BioDelivery Sciences International own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/02/2021Today9/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:BDSI CIK1103021 Webwww.bdsi.com Phone(919) 582-9050Fax919-582-9051Employees200Year Founded1997Profitability EPS (Trailing Twelve Months)$0.83 Trailing P/E Ratio6.74 Forward P/E Ratio14.71 P/E GrowthN/ANet Income$84.86 million Net Margins50.90% Pretax Margin17.77% Return on Equity21.25% Return on Assets10.56% Debt Debt-to-Equity Ratio0.29 Current Ratio2.45 Quick Ratio2.17 Sales & Book Value Annual Sales$166.70 million Price / Sales3.46 Cash Flow$0.36 per share Price / Cash Flow15.42 Book Value$1.90 per share Price / Book2.94Miscellaneous Outstanding Shares103,229,000Free Float92,927,000Market Cap$577.05 million OptionableOptionable Beta0.56 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:BDSI) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioDelivery Sciences International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioDelivery Sciences International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.